whitish papules occurred on the face and neck of the patient. The papules increased in number and size and were resistant to topical application of steroids and vitamin D analoga. Simultaneously, the psoriasis flared up. The patient presented at our department with more than 50 fleshcoloured partly umbilicated papules and nodules of up to 1 cm in diameter ( fig. 1 ) that were diagnosed as disseminated giant mollusca contagiosa (MC).
We report a 45-year-old female patient who was referred to our department because of a psoriasis flare-up and the development of skin papules following retreatment with efalizumab. She had been suffering from recalcitrant psoriasis vulgaris for 20 years and had a long history of different treatment modalities including extensive (repeat) UV therapy and therapy with fumaric acid esters. Complete remission was achieved after efalizumab 1 mg/ kg/week s.c. had been administered for 12 weeks. After the remission had been sustained by efalizumab treatment for another 3 months, the drug was discontinued on advice of the physician. Two months later, the patient had a severe psoriasis relapse and the efalizumab treatment regimen was resumed. Three weeks later, eruptive
Comment
MC is a common epidermotropic pox virus infection in children. The virus is transferred by direct skin contact. In patients with regular immune function, the virus induces an effective antiviral response which prevents the manifestation of MC or leads to a complete remission of MC. As contact with the virus and mounting of a virus-specific immune response usually occur during childhood, MC infections are rarely found in adults. Predisposing factors in adults with MC are atopic dermatitis and a suppressed immune system. MC infections are therefore common in patients with HIV infection or transplant patients.
In contrast to patients with atopic dermatitis, psoriasis patients hardly experience bacterial or viral skin infections. The low rate of skin infections in psoriasis patients is attributed to the activation of antimicrobial defence mechanisms in inflamed skin. However, immunosuppressive systemic antipsoriatic therapy can predispose patients to skin infections. Accordingly, MC has been reported in psoriasis patients during immunosuppressive therapy such as methotrexate [1] or during infliximab treatment in combination with other immunosuppressive drugs [2, 3] .
Efalizumab is a CD11a antibody approved for the treatment of recalcitrant moderate to severe psoriasis vulgaris. Efalizumab inhibits T-cell activation and parWeisenseel/Kuznetsov/Flaig/Prinz Dermatology 2008;217:85-86 86 ticularly T-cell transmigration from blood vessels into the skin [4] . The rate of infections or malignant tumours during efalizumab treatment for psoriasis vulgaris is generally not increased [5, 6] . Therefore, efalizumab is considered as a safe longterm treatment regimen.
The exacerbation of MC under efalizumab therapy reported here might indicate that under certain conditions efalizumab might assist viral infections to develop and defeat the immune system. While MC lesions in childhood normally measure 1-4 mm, giant-shaped MC of more than 5 mm in diameter can be found in HIV-positive patients and patients under immunosuppressive therapy [7] . Although case reports provide only little evidence in general, they may prove ne cessary to raise the awareness of unanticipated adverse events in this new class of psoriasis drugs. This first published case of MC during efalizumab treatment demonstrates that biological agents do not only offer new and effective treatment options for chronic inflammatory diseases, but may also confront us with atypical or unexpected infections. 
